Strengthens balance sheet with non-dilutive capital at an attractive cost Competitive process results in the sale of 30% of the...
Program to aid in patient access to Surgalign’s Coflex® Interlaminar Stabilization® andSImmetry® SI Joint Fusion Systems DEERFIELD, Ill., July 14, 2022...
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J....
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the...
PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studiesFLORHAM PARK, N.J., July 14, 2022 (GLOBE...
Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and...
Credited with performing the first ever endovascular repair procedure in 1990TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD,...
NEW ORLEANS and LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing...
Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:...
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million...
Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland,...
Arecor Therapeutics plc(“Arecor” or the “Group”) BUSINESS UPDATE Pipeline for future revenue generating partnered collaborations is strong with further deals...
As of the July 5, 2022, data cutoff, early CNM-Au8® treatment resulted in a significant survival benefit (5 CNM-Au8 deaths...
Confirmed safety profile at 300 mg/m2 or 1.5 times the therapeutic dose of docetaxel aloneConfirmed low levels of free docetaxel...
Dupixent®(dupilumab) Phase 3 trial shows positive results in children 1 to 11 years of age with eosinophilic esophagitis First and...
STAR-LLD well tolerated with no dose-related toxicity or adverse eventsSTAR LLD achieved 90% bioavailability across all dosesPlasma levels showed a...
∙ Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected...
By Greg Kefer at Lifelink Systems COVID-19 has placed clinical research in the spotlight. Americans have been anxiously following vaccine development...